COMMUNIQUÉS West-GlobeNewswire

Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
31/05/2024
HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported [...]
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
31/05/2024
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative [...]
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to July 3, 2024
31/05/2024
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”) a special purpose acquisition company, announced that today, its sponsor, Vision Sensing, LLC, [...]
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31/05/2024
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in [...]
Fortrea lance une solution complète pour améliorer la diversité et l’inclusion dans la recherche clinique
31/05/2024
Exploitation des données en conditions réelles, des connaissances des patients et adoption d’un processus systématique pour développer, concrétiser et mesurer l’efficacité des plans d’action en faveur de la diversité [...]
EAACI Congress Kicks Off in Valencia, Spain
31/05/2024
Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) -- The EAACI International Congress has commenced with the slogan “Revolutionizing patient [...]
Smart for Life to be Featured in Whole Foods Magazine Highlighting Product Offerings, Strategic Acquisitions and Expansion Initiatives
31/05/2024
Company Representatives to Explore Strategies for Emerging Growth Companies in the Health & Wellness Sector MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL), a prominent leader in the [...]
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31/05/2024
Local startup Oncobiotix to receive $100,000 to advance cancer and microbiome research CALGARY, Alberta, May 31, 2024 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is pleased to announce the latest recipient of the [...]
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
31/05/2024
If approved, IXCHIQ ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV) Decision on EU marketing authorization expected in the third quarter of 2024 Saint Herblain (France), May 31 [...]
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son vaccin contre le chikungunya
31/05/2024
En cas d’approbation, IXCHIQ ® deviendra le premier vaccin disponible dans l'UE contre le virus du chikungunya (CHIKV) Une décision sur la demande d’autorisation de mise sur le marché européen est attendue au troisième [...]
OPKO Health to Participate in the Jefferies Global Healthcare Conference
31/05/2024
MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott [...]
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
31/05/2024
COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval [...]
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, [...]
AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
31/05/2024
COMMUNIQUE DE PRESSE RESUME DE LA CONFERENCE VIRTUELLE DU 30 MAI 2024 FAISANT LE POINT SUR LA DEMANDE D'AUTORISATION CONDITIONNELLE DE MISE SUR LE MARCHE DU MASITINIB DANS LE TRAITEMENT DE LA SCLEROSE LATERALE [...]
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
31/05/2024
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, May 31, 2024 – Zealand [...]
JDRF Walk to Cure Diabetes
31/05/2024
Throughout June close to 50 communities will be gathering across Canada to raise funds for type 1 diabetes research TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- The JDRF Walk to Cure Diabetes is the largest fundraising [...]
Marche pour la guérison du diabète FRDJ
31/05/2024
Tout au long du mois de juin, près de 50 communautés se réuniront dans tout le Canada pour amasser des fonds en faveur de la recherche sur le diabète de type 1 TORONTO, 31 mai 2024 (GLOBE NEWSWIRE) -- La Marche pour la [...]
DBV Technologies Announces Plan to Implement ADS Ratio Change
31/05/2024
Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage [...]
DBV Technologies annonce son intention de modifier le ratio d'ADS
31/05/2024
Châtillon, France, le 31 mai 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), une société [...]

Pages